Healthcare Industry News: VIASYS Healthcare
News Release - January 8, 2007
VIASYS Receives FDA Approval to Market Its PulmoLife(TM) Spirometry ScreenerCONSHOHOCKEN, Pa.--(HSMN NewsFeed)--VIASYS Respiratory Care Inc., a subsidiary of VIASYS Healthcare Inc. (NYSE:VAS ) received approval to market its PulmoLife spirometry screener by the United States Food and Drug Administration. The PulmoLife screener is a new device designed for quick and easy assessment of lung disease associated with airflow obstruction known as Chronic Obstructive Pulmonary Disease (COPD).
The PulmoLife device uses spirometry to measure lung function. According to the National Institutes of Health, "Spirometry is the most sensitive and commonly used test of lung functions. It can detect COPD long before you have significant symptoms." Early detection of decreased lung function by the PulmoLife device may help a smoker realize the damage smoking can cause and encourage them to seek smoking cessation advice as well as appropriate medical treatment.
ABOUT VIASYS Healthcare INC.
VIASYS Healthcare Inc. is a global, research-based medical technology company focused on respiratory, neurology, medical disposable and orthopedic products. VIASYS products are marketed under well-recognized trademarks including, among others, AVEA®, BEAR®, BIRD®, CORFLO®, CORPAK®, CORTRAK®, EME®, GRASON-STADLER®, JAEGER(TM), LYRA®, MEDELEC®, MICROGAS®, NAVIGATOR®, NICOLET®, NicoletOne(TM), PULMONETIC(TM), SENSORMEDICS®, TECA®, TECOMET(TM), VELA® and VMAX®. VIASYS is headquartered in Conshohocken, PA, and its businesses are conducted through its Respiratory Care, NeuroCare, MedSystems and Orthopedics business units. More information can be found at http://www.viasyshealthcare.com.
Source: VIASYS Healthcare
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.